Diffuse Gastric Adenocarcinoma
NCI Definition: An adenocarcinoma arising from the stomach. Microscopically, it is characterized by the presence of a diffuse infiltrate, composed of individual adenocarcinoma cells or groups of adenocarcinoma cells in a fibrous or mucoid stroma. Many cells contain mucin droplets, producing a signet-ring configuration. 
Diffuse gastric adenocarcinomas most frequently harbor alterations in TP53 and CDH1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and CDH1 Mutation are the most common alterations in diffuse gastric adenocarcinoma .
There is 1 clinical trial for diffuse gastric adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains diffuse gastric adenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for diffuse gastric adenocarcinoma clinical trials .
Crizotinib is the most common intervention in diffuse gastric adenocarcinoma clinical trials.
Significant Genes in Diffuse Gastric Adenocarcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for diffuse gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and diffuse gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.